GlassScriptPhysician profile
Manasiben A Patel
NPI 1164177440
$3,377.78
in general payments reported to CMS, 2019-2025
35 companies · $810 in 2025
The $810 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.50 · 2023: $598 · 2024: $1,957 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Consulting Fee: $1,490 · Education: $380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.82 |
| Consulting Fee | $1,490.00 |
| Education | $380.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,739.78 | 2023-2025 | Trodelvy |
| Janssen Biotech, INC. | $179.82 | 2023-2025 | Erleada, Darzalex, Rybrevant |
| Ipsen Biopharmaceuticals, INC | $136.98 | 2023-2025 | Onivyde, Somatuline Depot |
| Astellas Pharma US INC | $116.63 | 2023-2024 | Padcev |
| Abbvie INC. | $114.90 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.06 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $91.72 | 2023-2025 | Monoferric, Cosela |
| Daiichi Sankyo INC. | $71.90 | 2023-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $69.72 | 2023-2024 | Keytruda, Lynparza |
| Regeneron Healthcare Solutions, INC. | $55.53 | 2024-2025 | Libtayo |
| Genzyme Corporation | $51.02 | 2023-2025 | |
| Sumitomo Pharma America, INC. | $48.80 | 2023 | Orgovyx |
| Incyte Corporation | $48.19 | 2023-2025 | Jakafi |
| Genmab U.S., INC. | $40.05 | 2023-2025 | Epkinly |
| Pfizer INC. | $39.07 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $38.63 | 2023 | Kyprolis, Blincyto |
| Blueprint Medicines Corporation | $33.32 | 2024-2025 | Ayvakit |
| Lilly USA, LLC | $32.41 | 2024 | Verzenio, Jaypirca, Retevmo |
| Octapharma USA, INC. | $32.08 | 2024 | Panzyga, Octagam Immune Globulin (Human) |
| Emd Serono, INC. | $31.10 | 2023 | Bavencio, Tepmetko |
| E.R. Squibb & Sons, L.L.C. | $29.45 | 2024 | Opdivo, Krazati |
| Novartis Pharmaceuticals Corporation | $26.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.34 | 2025 | Fruzaqla |
| Apellis Pharmaceuticals, INC. | $20.60 | 2024 | Empaveli |
| Myriad Genetic Laboratories, INC. | $20.46 | 2025 | Myrisk |
| Taiho Oncology, INC. | $19.00 | 2024 | |
| Sobi, INC | $18.66 | 2024 | |
| Puma Biotechnology, INC. | $18.06 | 2025 | |
| Array Biopharma INC | $17.61 | 2024 | Braftovi, Tukysa, Mektovi |
| Agios Pharmaceuticals, INC. | $17.56 | 2023 | Pyrukynd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.33 | 2025 | |
| Glaxosmithkline, LLC. | $17.31 | 2023 | Zejula, Jemperli |
| Pharmaessentia USA Corporation | $16.89 | 2025 | Besremi |
| Alexion Pharmaceuticals, INC. | $15.83 | 2023 | Ultomiris |
| Novo Nordisk INC | $12.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manasiben Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.